As an early investor in Entrada Therapeutics, we are pleased to share their progress on their exon-skipping programs in Duchenne.
For Exon 44: Entrada completed enrollment for the first cohort of the ex-US ELEVATE-44-201 study for those amenable to skipping exon 44, and are on track to report data in Q2 2026. They expect to initiate a Phase 1b study in the US for ambulatory and non-ambulatory adults with Duchenne in 2026.
For Exon 45: Entrada has dosed the first participant in the ELEVATE-45-201 study for those amenable to skipping exon 45, and will report data from the first cohort in mid-2026.
For Exon 50: Entrada filed for regulatory authorization in the U.K. for the ELEVATE-50-201 study to begin the study there by the end of 2026.
Link to press release:
Link to press release: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-reports-third-quarter-2025-financial
The post Updates on Entrada’s exon skipping clinical trials appeared first on CureDuchenne.